ErbB3 调控缺氧诱导的肺动脉高压内皮功能障碍
该研究通过微阵列、免疫荧光和蛋白印迹分析,结合缺氧及 Sugen 诱导的啮齿类 PH 模型,发现 ErbB3 在 PH 患者血清、肺组织、远端肺动脉及肺动脉内皮细胞中显著上调,并通过 YB-1/HIF-1/2α 正反馈环路促进内皮增殖和血管重构;MM-121 抗体对缺氧诱导的 PH 具有预防和治疗作用。
要点
- ErbB3 在 PH 患者血清、肺组织及肺动脉内皮细胞中显著上调,可作为新型生物标志物。
- ErbB3 通过 YB-1 核转位促进 HIF-1/2α 转录,形成 ErbB3-骨膜蛋白-HIF 正反馈环路。
- 抗 ErbB3 单抗 MM-121 在缺氧诱导 PH 模型中显示预防和治疗效果。
核心结论
- ErbB3 是 PH 的新型生物标志物和有前景的治疗靶点。
研究设计与样本
- 研究采用微阵列、免疫荧光和蛋白印迹分析,并在慢性缺氧及 Sugen 诱导的啮齿类 PH 模型中验证 ErbB3 功能。
- 使用腺相关病毒介导的 ErbB3 过表达、全身性敲除或内皮细胞特异性敲低,并结合人肺动脉内皮细胞和平滑肌细胞阐明机制。
主要发现
- 与健康供者相比,PH 患者血清、肺组织、远端肺动脉及分离的肺动脉内皮细胞中 ErbB3 显著上调。
- ErbB3 过表达刺激缺氧诱导的内皮细胞增殖,加重肺动脉重构,升高右心室收缩压并促进右心室肥厚。
- 全身性敲除或内皮细胞特异性敲除 ErbB3 产生相反效应。
- 免疫共沉淀和蛋白质组学鉴定 YB-1 为 ErbB3 下游靶点,ErbB3 诱导 YB-1 核转位并促进 HIF-1/2α 转录。
- 鉴定出 ErbB3-骨膜蛋白-HIF-1/2α 正反馈环路介导疾病进展。
临床怎么用
- ErbB3 可作为 PH 的候选生物标志物用于疾病识别。
- MM-121 等抗 ErbB3 抗体可能成为缺氧诱导 PH 的预防或治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension, characterized by vascular remodeling, currently lacks curative therapeutic options. The dysfunction of pulmonary artery endothelial cells plays a pivotal role in the initiation and progression of pulmonary hypertension (PH). ErbB3 (human epidermal growth factor receptor 3), also recognized as HER3, is a member of the ErbB family of receptor tyrosine kinases. METHODS: Microarray, immunofluorescence, and Western blotting analyses were conducted to investigate the pathological role of ErbB3. Blood samples were collected for biomarker examination from healthy donors or patients with hypoxic PH. The pathological functions of ErbB3 were further validated in rodents subjected to chronic hypoxia- and Sugen-induced PH, with or without adeno-associated virus-mediated ErbB3 overexpression, systemic deletion, or endothelial cell-specific ErbB3 knockdown. Primary human pulmonary artery endothelial cells and pulmonary artery smooth muscle cells were used to elucidate the underlying mechanisms. RESULTS: ErbB3 exhibited significant upregulation in the serum, lungs, distal pulmonary arteries, and pulmonary artery endothelial cells isolated from patients with PH compared with those from healthy donors. ErbB3 overexpression stimulated hypoxia-induced endothelial cell proliferation, exacerbated pulmonary artery remodeling, elevated systolic pressure in the right ventricle, and promoted right ventricular hypertrophy in murine models of PH. Conversely, systemic deletion or endothelial cell-specific knockout of ErbB3 yielded opposite effects. Coimmunoprecipitation and proteomic analysis identified YB-1 (Y-box binding protein 1) as a downstream target of ErbB3. ErbB3 induced nuclear translocation of YB-1 and subsequently promoted hypoxia-inducible factor 1/2α transcription. A positive loop involving ErbB3-periostin-hypoxia-inducible factor 1/2α was identified to mediate the progressive development of this disease. MM-121, a human anti-ErbB3 monoclonal antibody, exhibited both preventive and therapeutic effects against hypoxia-induced PH. CONCLUSIONS: Our study reveals, for the first time, that ErbB3 serves as a novel biomarker and a promising target for the treatment of PH.
引用
- Bian JS, Chen J, Zhang J, et al. ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension. Circulation. 2024. PMID: 38214194. doi:10.1161/CIRCULATIONAHA.123.067005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。